Published in Am J Case Rep on March 29, 2013
Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients. Ann Intern Med (1993) 2.91
Fulminant and subfulminant liver failure: definitions and causes. Semin Liver Dis (1986) 2.39
Toxic injury to hepatic sinusoids: sinusoidal obstruction syndrome (veno-occlusive disease). Semin Liver Dis (2002) 2.17
Cellular target of cyclophosphamide toxicity in the murine liver: role of glutathione and site of metabolic activation. Hepatology (1996) 1.34
The effect of busulphan on the pharmacokinetics of cyclophosphamide and its 4-hydroxy metabolite: time interval influence on therapeutic efficacy and therapy-related toxicity. Bone Marrow Transplant (2000) 1.17
High exposures to bioactivated cyclophosphamide are related to the occurrence of veno-occlusive disease of the liver following high-dose chemotherapy. Br J Cancer (2006) 1.16
Veno-occlusive disease of the liver associated with oral contraceptives: case report and review of literature. Hum Pathol (1976) 0.99
Veno occlusive disease: update on clinical management. World J Gastroenterol (2007) 0.98
A successful liver transplantation for refractory hepatic veno-occlusive disease originating from cord blood transplantation. Am J Transplant (2002) 0.90
Hepatic veno-occlusive disease. Am J Med (1986) 0.87
Fatal pulmonary venoocclusive disease after use of oral contraceptives. Am Heart J (1992) 0.83
Orthotopic liver transplantation for veno-occlusive disease complicating autologous bone marrow transplantation. Transplantation (1997) 0.82
Liver transplantation for sinusoidal obstructive syndrome (veno-occlusive disease): case report with review of the literature and the UNOS database. Clin Transplant (2008) 0.80
Laboratory markers of veno-occlusive disease in the course of bone marrow and subsequent liver transplantation. Bone Marrow Transplant (1997) 0.79
Orthotopic liver transplantation for life-threatening veno-occlusive disease of the liver after allogeneic bone marrow transplant. Bone Marrow Transplant (1991) 0.79
Fulminant liver failure due to severe veno-occlusive disease after haematopoietic cell transplantation: a depressing experience. QJM (2004) 0.78
Hepatic veno-occlusive disease in a case of polymyositis associated with thrombotic thrombocytopenic purpura/hemolytic uremic syndrome. Intern Med (1998) 0.78
Cryptogenic fulminant hepatic failure in infancy: report of 2 cases with unique vascular obstructive changes in native livers. Liver Transpl (2006) 0.78
Hemophagocytic syndrome associated with fatal veno-occlusive disease in the liver. Intern Med (2007) 0.78
Management of hepatocellular carcinoma in Japan: Consensus-Based Clinical Practice Guidelines proposed by the Japan Society of Hepatology (JSH) 2010 updated version. Dig Dis (2011) 3.74
Hepatic steatosis is a risk factor for hepatocellular carcinoma in patients with chronic hepatitis C virus infection. Cancer (2003) 2.29
Clinical outcomes of endoscopic submucosal dissection for early gastric cancer by indication criteria. Digestion (2009) 2.01
Usefulness of oral prednisolone in the treatment of esophageal stricture after endoscopic submucosal dissection for superficial esophageal squamous cell carcinoma. Gastrointest Endosc (2011) 1.94
Efficacy and safety of entecavir in lamivudine-refractory patients with chronic hepatitis B: randomized controlled trial in Japanese patients. J Gastroenterol Hepatol (2008) 1.78
A novel murine model of Graves' hyperthyroidism with intramuscular injection of adenovirus expressing the thyrotropin receptor. J Immunol (2002) 1.59
Cytokine gene polymorphisms in Japanese patients with hepatitis B virus infection--association between TGF-beta1 polymorphisms and hepatocellular carcinoma. J Hepatol (2004) 1.52
Antiangiogenic gene therapy for hepatocellular carcinoma using angiostatin gene. Hepatology (2003) 1.52
General rules for recording endoscopic findings of esophagogastric varices (2nd edition). Dig Endosc (2010) 1.51
Influence of interleukin-10 gene promoter polymorphisms on disease progression in patients chronically infected with hepatitis B virus. Am J Gastroenterol (2002) 1.50
Differential effects of calcineurin inhibitors, tacrolimus and cyclosporin a, on interferon-induced antiviral protein in human hepatocyte cells. Liver Transpl (2008) 1.50
Outcomes of living donor liver transplantation for hepatitis C virus-positive recipients in Japan: results of a nationwide survey. Transpl Int (2014) 1.49
Are bile duct lesions of primary biliary cirrhosis distinguishable from those of autoimmune hepatitis and chronic viral hepatitis? Interobserver histological agreement on trimmed bile ducts. J Gastroenterol (2005) 1.48
CD14 expression and Kupffer cell dysfunction in non-alcoholic steatohepatitis: superparamagnetic iron oxide-magnetic resonance image and pathologic correlation. J Gastroenterol Hepatol (2012) 1.47
Large blood pressure variability aggravates arteriolosclerosis and cortical sclerotic changes in the kidney in hypertensive rats. Circ J (2014) 1.45
MicroRNA signatures in Helicobacter pylori-infected gastric mucosa. Int J Cancer (2010) 1.44
Molecular diagnosis of activating EGFR mutations in non-small cell lung cancer using mutation-specific antibodies for immunohistochemical analysis. Clin Cancer Res (2010) 1.44
Nonsteroidal anti-inflammatory drug-induced vanishing bile duct syndrome treated with plasmapheresis. J Pediatr Gastroenterol Nutr (2013) 1.41
Management of esophageal stricture after complete circular endoscopic submucosal dissection for superficial esophageal squamous cell carcinoma. BMC Gastroenterol (2011) 1.41
Changes in serum levels of hepatocyte growth factor in patients undergoing adult-to-adult living-donor liver transplantation. Transplantation (2003) 1.40
Practical utility and objectivity: does evaluation of peritoneal elastic laminal invasion in colorectal cancer overcome these contrary problems? Am J Surg Pathol (2014) 1.40
Diagnosing clinical subsets of autoimmune liver diseases based on a multivariable model. J Gastroenterol (2005) 1.38
Different mechanisms for anti-tumor effects of low- and high-dose cyclophosphamide. Oncol Rep (2006) 1.36
MicroRNAs and esophageal squamous cell carcinoma. Digestion (2010) 1.35
Genome-wide association study identifies TNFSF15 and POU2AF1 as susceptibility loci for primary biliary cirrhosis in the Japanese population. Am J Hum Genet (2012) 1.32
High viral load is a risk factor for hepatocellular carcinoma in patients with chronic hepatitis B virus infection. J Gastroenterol Hepatol (2004) 1.32
Loss of PTEN expression by blocking nuclear translocation of EGR1 in gefitinib-resistant lung cancer cells harboring epidermal growth factor receptor-activating mutations. Cancer Res (2010) 1.31
Tumor growth suppression in pancreatic cancer by a putative metastasis suppressor gene Cap43/NDRG1/Drg-1 through modulation of angiogenesis. Cancer Res (2006) 1.28
Intrahepatic biloma formation (bile duct necrosis) after transcatheter arterial chemoembolization. AJR Am J Roentgenol (2003) 1.27
Initiation of genome instability and preneoplastic processes through loss of Fhit expression. PLoS Genet (2012) 1.27
A serum "sweet-doughnut" protein facilitates fibrosis evaluation and therapy assessment in patients with viral hepatitis. Sci Rep (2013) 1.27
Prognostic impact of spontaneous tumor rupture in patients with hepatocellular carcinoma: an analysis of 1160 cases from a nationwide survey. Ann Surg (2014) 1.25
Clinicopathologic analysis of combined hepatocellular-cholangiocarcinoma according to the latest WHO classification. Am J Surg Pathol (2013) 1.23
Portal vein invasion and intrahepatic micrometastasis in small hepatocellular carcinoma by gross type. Hepatol Res (2003) 1.23
Erlotinib resistance in lung cancer cells mediated by integrin β1/Src/Akt-driven bypass signaling. Cancer Res (2013) 1.23
MiRNA-205 modulates cellular invasion and migration via regulating zinc finger E-box binding homeobox 2 expression in esophageal squamous cell carcinoma cells. J Transl Med (2011) 1.22
Antiangiogenic property of pigment epithelium-derived factor in hepatocellular carcinoma. Hepatology (2004) 1.22
Comparison of resection and ablation for hepatocellular carcinoma: a cohort study based on a Japanese nationwide survey. J Hepatol (2012) 1.19
Peroral endoscopic myotomy for esophageal achalasia: clinical impact of 28 cases. Dig Endosc (2013) 1.19
Interferon-alpha sensitizes human hepatoma cells to TRAIL-induced apoptosis through DR5 upregulation and NF-kappa B inactivation. Oncogene (2003) 1.18
Beta-catenin expression in hepatocellular carcinoma: a possible participation of beta-catenin in the dedifferentiation process. J Gastroenterol Hepatol (2002) 1.18
Management of complications associated with endoscopic submucosal dissection/ endoscopic mucosal resection for esophageal cancer. Dig Endosc (2013) 1.18
Viral load is a significant prognostic factor for hepatitis B virus-associated hepatocellular carcinoma. Cancer (2002) 1.16
Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel. Lung Cancer (2008) 1.16
Alpha-fetoprotein above normal levels as a risk factor for the development of hepatocellular carcinoma in patients infected with hepatitis C virus. J Gastroenterol (2010) 1.13
Intraductal neoplasm of the intrahepatic bile duct: clinicopathological study of 24 cases. World J Gastroenterol (2012) 1.12
Clinicopathological study of scirrhous hepatocellular carcinoma. J Gastroenterol Hepatol (2006) 1.12
Significance of programmed cell death-ligand 1 expression and its association with survival in patients with small cell lung cancer. J Thorac Oncol (2015) 1.11
Clinical outcomes of endoscopic submucosal dissection in elderly patients with early gastric cancer. Eur J Gastroenterol Hepatol (2010) 1.11
Diagnostic accuracy of imaging for liver cirrhosis compared to histologically proven liver cirrhosis. A multicenter collaborative study. Intervirology (2008) 1.10
Rapid fabricating technique for multi-layered human hepatic cell sheets by forceful contraction of the fibroblast monolayer. PLoS One (2013) 1.10
Application of a new histological staging and grading system for primary biliary cirrhosis to liver biopsy specimens: Interobserver agreement. Pathol Int (2010) 1.10
Obstructing spontaneous major shunt vessels might not be mandatory to maintain adequate portal inflow in living donor liver transplantation. Transplantation (2014) 1.09
Superselective transarterial chemoembolization for hepatocellular carcinoma. Validation of treatment algorithm proposed by Japanese guidelines. J Hepatol (2011) 1.09
Evaluation of the mean and entropy of apparent diffusion coefficient values in chronic hepatitis C: correlation with pathologic fibrosis stage and inflammatory activity grade. Radiology (2011) 1.08
Short interfering RNA-directed inhibition of hepatitis B virus replication. FEBS Lett (2003) 1.08
Association between nonalcoholic fatty liver, markers of obesity, and serum leptin level in young adults. Am J Gastroenterol (2002) 1.08
Effectiveness of aquatic exercise and balneotherapy: a summary of systematic reviews based on randomized controlled trials of water immersion therapies. J Epidemiol (2009) 1.07
Overexpression of angiopoietin-1 and angiopoietin-2 in hepatocellular carcinoma. J Hepatol (2004) 1.07
Lens culinaris agglutinin-reactive alpha-fetoprotein and protein induced by vitamin K absence II are potential indicators of a poor prognosis: a histopathological study of surgically resected hepatocellular carcinoma. J Gastroenterol (2007) 1.06
Factors related to the curability of early gastric cancer with endoscopic submucosal dissection. Surg Endosc (2009) 1.05
Diffuse liver metastasis of small cell lung cancer causing marked hepatomegaly and fulminant hepatic failure. Intern Med (2010) 1.03
Clinicopathological study of nonalcoholic fatty liver disease in Japan: the risk factors for fibrosis. Liver Int (2007) 1.02
Interleukin-18 promoter polymorphisms and the disease progression of Hepatitis B virus-related liver disease. Transl Res (2008) 1.02
A 16-year experience in performing hepatic resection in 303 patients with hepatocellular carcinoma: 1985-2000. Surgery (2002) 1.01
Role of growth hormone, insulin-like growth factor 1 and insulin-like growth factor-binding protein 3 in development of non-alcoholic fatty liver disease. Hepatol Int (2007) 1.01
Usefulness of D2-40 immunohistochemistry for differentiation between kaposiform hemangioendothelioma and tufted angioma. J Cutan Pathol (2006) 1.01
Abrogation of constitutive STAT3 activity sensitizes human hepatoma cells to TRAIL-mediated apoptosis. J Hepatol (2007) 1.00
Association between liver fibrosis and insulin sensitivity in chronic hepatitis C patients. Am J Gastroenterol (2006) 1.00
Expression of HER2 and estrogen receptor alpha depends upon nuclear localization of Y-box binding protein-1 in human breast cancers. Cancer Res (2008) 1.00